

理委員会の審査を受け、指針に従い臨床情報は匿名化し個人情報に十分配慮した。

個人遺伝子情報に関する保護と管理は、「ヒトゲノム・遺伝子解析研究に関する倫理指針」に基づいて行うものとした。試料・データはすべて連結可能匿名化とし、個人識別に関するデータは個人識別情報管理分担者が管理した。データは研究室に設置した専用コンピューターにて一括管理し、データアクセスは研究従事者がパスワードを用いて行った。また、各症例の遺伝子発現情報の管理、情報解析も専用コンピューターに一括して保存し、部外者のアクセスを禁じた。

### C. 研究結果

1. 初回観察時の平均HbA<sub>1c</sub>、BMI、HOMA-IRは7.5%、29kg/m<sup>2</sup>、3.9であった。
2. 2型糖尿病、高血圧、脂質異常症、メタボリックシンドロームの罹患率は各々76、35、64、38%であった。
3. 平均観察期間3.0±2.1年間で肝線維化は11人（28%、FL：NASH 10：1）が悪化、12人（31%、FL：NASH 3：9）が改善、16人（41%、FL：NASH 7：9）が不变であった。
4. 単変量解析では、線維化改善群で初回肝生検時のAST ( $P=0.04$ ) およびHbA<sub>1c</sub>低下量 ( $\Delta HbA_{1c}$ ,  $P=0.01$ ) が有意に高値を示した。
5. 一方、BMI やインスリン抵抗性マーカーであるHOMA-IR、QUICKI、筋

インスリン抵抗性、肝インスリン抵抗性はいずれも線維化進展と相關しなかった。

6. 多変量解析（重回帰分析）により年齢、性、BMIで補正すると、 $\Delta HbA_{1c}$ のみが肝線維化進展の予測因子であった ( $P=0.03$ )。
7. 各種治療法をCox比例ハザードモデルで解析したところ、インスリン治療が肝線維化を改善する独立した予知因子であった。

### D. 考察

血糖コントロールの改善は、BMI、インスリン抵抗性にも増して、日本人NAFLD患者の肝病理改善を予知する。分担研究者は以前に、2型糖尿病患者の肝臓では、非糖尿病患者に比し、血管新生因子、線維化のマスター因子TGF- $\beta$  ファミリー、コラーゲン等の遺伝子発現が亢進することを観察しており、今回の知見を裏付けるものと考える。

### E. 結論

肥満といった既知のNASH危険因子だけでなく、厳格な血糖コントロールがNAFLDの肝線維化阻止のために重要である。また、超速効型インスリン各食前投与を主体としたインスリン治療が、NAFLDの病理を改善する可能性が示唆された。

G. 研究発表

1. 論文発表

1. Ando H, Ushijima K, Kumazaki M, Takamura T, Yokota N, Saito T, Irie S, Kaneko S, Fujimura A: Influence of age on clock gene expression in peripheral blood cells of healthy women. *J Gerontol A Biol Sci Med Sci* 65:9-13, in press
2. Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, Kurita S, Arai K, Yamashita T, Sasaki M, Nakanuma Y, Kaneko S: Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. *Diabetes Care* 33:284-286, 2010
3. Sakurai M, Takamura T, Miura K, Kaneko S, Nakagawa H: Abnormal liver function tests and metabolic syndrome--is fatty liver related to risks for atherosclerosis beyond obesity? *Intern Med* 48:1573-1574, 2009
4. Sakurai M, Takamura T, Miura K, Kaneko S, Nakagawa H: Middle-aged Japanese women are resistant to obesity-related metabolic abnormalities. *Metabolism* 58:456-459, 2009
5. Sakurai M, Miura K, Takamura T, Ishizaki M, Morikawa Y, Nakamura K, Yoshita K, Kido T, Naruse Y, Kaneko S, Nakagawa H: J-shaped relationship between waist circumference and subsequent risk for Type 2 diabetes: an 8-year follow-up of relatively lean Japanese individuals. *Diabet Med* 26:753-759, 2009
6. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, Noda H, Nabemoto S, Kurita S, Ota T, Ando H, Miyamoto K, Kaneko S: Palmitate induces insulin resistance in H4IEC3 hepatocytes through reactive oxygen species produced by mitochondria. *J Biol Chem* 284:14809-14818, 2009
7. Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S: CD14+monocytes are vulnerable and functionally impaired under ER stress in patients with type 2 diabetes. *Diabetes*, 2009 Dec 3. [Epub ahead of print]
8. Ando H, Ushijima K, Yanagihara H, Hayashi Y, Takamura T, Kaneko S, Fujimura A: Clock gene expression in the liver and adipose tissues of non-obese type 2 diabetic Goto-Kakizaki rats. *Clin Exp Hypertens* 31:201-207, 2009
9. Ando H, Takamura T, Matsuzawa-Nagata N, Shima KR, Nakamura S, Kumazaki M, Kurita S, Misu H, Togawa N, Fukushima T, Fujimura A, Kaneko S: The hepatic circadian clock is preserved in a lipid-induced mouse model of non-alcoholic steatohepatitis. *Biochem Biophys Res Commun* 380:684-688, 2009
10. Ando H, Takamura T, Matsuzawa-Nagata N, Shima KR, Eto T, Misu H, Shiramoto M, Tsuru T, Irie S, Fujimura A, Kaneko S: Clock gene expression in peripheral leucocytes of patients with type 2 diabetes. *Diabetologia* 52:329-335, 2009
11. Uno M, Kurita S, Misu H, Ando H, Ota T,

- Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, Nakanuma Y, Kaneko S, Takamura T: Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis. *Hepatology* 48:109-118, 2008
12. Takeshita Y, Takamura T, Minato H, Misu H, Ando H, Yamashita T, Ikeda H, Nakanuma Y, Kaneko S: Transformation of p53-positive papillary thyroid carcinoma to anaplastic carcinoma of the liver following postoperative radioactive iodine-131 therapy. *Intern Med* 47:1709-1712, 2008
  13. Takeshita Y, Takamura T, Ando H, Hamaguchi E, Takazakura A, Matsuzawa-Nagata N, Kaneko S: Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes. *Eur J Pharmacol* 579:426-432, 2008
  14. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, Shimizu A, Kurita S, Takeshita Y, Ando H, Honda M, Kaneko S: Obesity Upregulates Genes Involved in Oxidative Phosphorylation in Livers of Diabetic Patients. *Obesity (Silver Spring)*, 2008
  15. Sakurai M, Takamura T, Miura K, Kaneko S, Nakagawa H: BMI may be better than waist circumference for defining metabolic syndrome in Japanese women. *Diabetes Care* 31:e12, 2008
  16. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, Ota T, Yokoyama M, Honda M, Miyamoto K, Kaneko S: Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. *Metabolism* 57:1071-1077, 2008
  17. Kurita S, Takamura T, Ota T, Matsuzawa-Nagata N, Kita Y, Uno M, Nabemoto S, Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S: Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. *Eur J Pharmacol* 588:316-324, 2008
  18. Kazama Y, Takamura T, Sakurai M, Shindo H, Ohkubo E, Aida K, Harii N, Taki K, Kaneshige M, Tanaka S, Shimura H, Endo T, Kobayashi T: New insulin sensitivity index from the oral glucose tolerance test. *Diabetes Res Clin Pract* 79:24-30, 2008
  19. Tsuchiyama N, Takamura T, Ando H, Sakurai M, Shimizu A, Kato K, Kurita S, Kaneko S: Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes. *Diabetes Care* 30:2583-2587, 2007
  20. Takamura T, Shimizu A, Komura T, Ando H, Zen Y, Minato H, Matsushita E, Kaneko S: Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis. *Intern Med* 46:579-581, 2007
  21. Takamura T, Sakurai M, Nakamura M, Shimizu A, Ota T, Misu H, Takeshita Y,

- Tsuchiyama N, Kurita S, Ando H, Kaneko S: Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. *Diabetes Res Clin Pract* 75:278-284, 2007
22. Takamura T, Honda M, Sakai Y, Ando H, Shimizu A, Ota T, Sakurai M, Misu H, Kurita S, Matsuzawa-Nagata N, Uchikata M, Nakamura S, Matoba R, Tanino M, Matsubara K, Kaneko S: Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. *Biochem Biophys Res Commun* 361:379-384, 2007
23. Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, Misu H, Kurita S, Sakurai M, Yokoyama M, Zen Y, Sasaki M, Nakanuma Y, Kaneko S: Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. *Metabolism* 56:1478-1485, 2007
24. Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakanuma Y, Miura K, Kaneko S: Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease. *J Gastroenterol* 42:312-317, 2007
25. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, Akahori H, Misu H, Sakurai M, Zen Y, Nakanuma Y, Kaneko S: Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. *Gastroenterology* 132:282-293, 2007
26. Ota T, Takamura T, Kaneko S: Pioglitazone in nonalcoholic steatohepatitis. *N Engl J Med* 356:1068; author reply 1068-1069, 2007
27. Misu H, Takamura T, Matsuzawa N, Shimizu A, Ota T, Sakurai M, Ando H, Arai K, Yamashita T, Honda M, Yamashita T, Kaneko S: Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyperglycaemia in livers of patients with type 2 diabetes. *Diabetologia* 50:268-277, 2007
28. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S: Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology* 46:1392-1403, 2007
29. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S: Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. *Am J Gastroenterol* 102:1939-1946, 2007
30. Kita Y, Mizukoshi E, Takamura T, Sakurai M, Takata Y, Arai K, Yamashita T, Nakamoto Y, Kaneko S: Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. *Metabolism* 56:1682-1688, 2007

2. 学会発表（講演・シンポジウム、筆頭のみ）
1. Takamura T, Hirofumi Misu, Shuichi Kaneko: Clinical and molecular pathology of type 2 diabetic liver. The 15th Korea-Japan Symposium on Diabetes Mellitus シンポジウム. Jeju. 2009年11月20-21日
  2. 篠 俊成, 御簾博文, 金子周一: 2型糖尿病患者の病態と酸化的リノ酸化遺伝子群の協調的発現異常. 第52回日本糖尿病学会年次学術集会 シンポジウム. 大阪. 2009年5月 (糖尿病 2009; 52 (Suppl. 1): S-39に掲載)
  3. 篠 俊成: 糖尿病学と肝臓病学の接点としての非アルコール性脂肪性肝疾患. 第52回日本糖尿病学会年次学術集会 教育講演. 大阪. 2009年5月 (糖尿病 2009; 52 (Suppl. 1): S-101に掲載)
  4. Takamura T Molecular mechanisms underlying fat-induced insulin resistance in the liver The 17th Korean Diabetes Association Summer Workshop & 2008 Symposium 招待講演. Seoul. 2008年8月 (Korean Diabetes Journal 2008; 32 (Suppl. 5): 22-23に掲載)
  5. 篠 俊成, 安藤 仁, 御簾博文, 金子周一: 肝臓のトランスクリプトームからみた糖尿病. 第22回日本糖尿病合併症学会 シンポジウム. つくば. 2007年10月 (糖尿病合併症 2007; 21 (Suppl. 1): 51に掲載) (糖尿病合併症 2008; 22: 136-140に Proceeding)
- H. 知的財産権の出願・登録状況
1. 特許取得
  - ① 篠 俊成、金子周一、御簾博文、山下太郎: 「糖尿病の病態と関連して発現変動する遺伝子群」、特願2005-125689
  - ② 篠 俊成、金子周一、本多政夫、酒井佳夫, 松原謙一: 「糖尿病の有無等を判定する方法」、特願2006-284625
  - ③ 篠 俊成、金子周一、御簾博文、高倉伸幸: 「インスリン抵抗性誘導・血管新生抑制作用を有する糖尿病関連肝臓由来分泌蛋白」、特願2006-206747、PCT(国際特許)出願(WO/2008/013324)
  - ④ 篠 俊成、金子周一、安藤仁、太田嗣人、御簾博文、栗田征一郎: 「非アルコール性脂肪肝炎予防または治療薬」、特願2007-277750
  - ⑤ 篠 俊成、金子周一、安藤仁、太田嗣人、御簾博文、栗田征一郎, 宇野将文: 「新規な肝疾患の予防または治療ならびにインスリン抵抗性改善剤」、特願2008-274758

### III. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイト ル名	書籍全体 の編集者 名	書籍 名	出版 社名	出版 地	出版 年	頁
岡上 武	非アルコール性脂肪性肝疾患の治療	林紀夫、日比紀文、上西紀夫、下瀬川徹	Annual Review 2010 消化器	中外医学社	東京	2010	131-135
岡上 武	脂肪肝,非アルコール性脂肪肝炎	高久史磨、尾形悦郎、黒川清、矢崎義雄	新臨牀内科学 第9版	医学書院	東京	2009	567-571
柳沼礼子, 池嶋健一, <u>渡辺純夫</u>	特集：肝疾患を生活習慣から考える II. 非アルコール性脂肪性肝障害の最近の動向 2 ) NASH: 病因、病態の新しい展開		成人病と生活習慣病		東京	2009	365-370
柳沼礼子, 池嶋健一, <u>渡辺純夫</u>	特集：生活習慣病クリニック 生活習慣病の予防と治療 効果的対策とは? 予防と治療 効果的対策; 非アルコール性肝疾患		Modern Physician		東京	2009	801-807
池嶋健一, <u>渡辺純夫</u>	NASH の治療 2 薬物療法		治療学		東京	2009	69-74

今一義、池嶋健一、渡辺純夫	NAFLD/NASH の発症機序		BIO Clinica		東京	2009	1154-1158
大西三朗、西原利治	NAFLD、NASH の病態と臨床			日本内科学会会誌	東京	2009	2101-2111
西原利治	非アルコール性脂肪肝炎の臨床の進展	林紀夫、日比紀文、上西紀夫、下瀬川徹	Annual Review 消化器 2009	中外医学社	東京	2009	157-166
宮本敬子、岡本宣人、西原利治	NASH 発症に関連する遺伝子多型	肝胆膵			東京	2009	1195-1199
高橋昌也、小野正文、西原利治	NASH 患者のインスリン抵抗性の特徴と肥満対策	消化器 内科				2009	369-376
小野正文、小笠原光成、西原利治、大西三朗	NASH モデル動物における発癌リスク	消化器科			東京	2009	97-104
廣瀬 亨、宮本 敬子、西原 利治	わが国における疫学と背景 肥満と NASH	治療学			東京	2009	1048-1050
宇都浩文、上村修二、坪内博仁	肝疾患の血清プロテオミクスを用いた診断	林紀夫、日比紀文、上西紀夫、下瀬川徹	Annual Review 消化器	中外医学社	東京	2009	200-208
宇都浩文、田ノ上 史郎、坪内 博仁	非アルコール性脂肪肝炎：NASH		臨床栄養			2009	737-742

宇都浩文、 呉 建、 坪内博仁	NASH の診断 1～バイオマ ーカー～		治療学			2009	1059- 1064
-----------------------	----------------------------	--	-----	--	--	------	---------------

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
岡上 武、西原利治、小野正文、角田圭雄、橋本悦子、田村信司、山田剛太郎、河田純男、工藤正俊	日本肝臓学会コンセンサス神戸 2009: NASH の診断と治療	肝臓	50	741-747	2009
Yasui K, Harano Y, Mitsuyoshi H, Tsugi K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, Yoshikawa T, Okanoue T	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus	J Gastroenterol	45	95-104	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H	Predictive value of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study	J Gastroenterol	44	952-963	2009
Gen Y, Yasui K, Zen K, Nakajima T, Tsugi K, Endo M, Mitsuyoshi H, Minami M, Itoh Y, Tanaka S, Taniwaki M, Arii S, Okanoue T, Yoshikawa T	A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells	Cancer lett	275	27-34	2009

Endo M, Yasui K, Nakajima T, Gen Y, Tsuji K, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M, Tanaka S, Arii S, <u>Okanoue T</u> , Yoshikawa T	Infrequent amplification of JUN in hepatocellular carcinoma	Anticancer Res	29	4989-4994	2009
Nishikawa T, Nakajima T, Katagishi T, Okada Y, Jo M, Kagawa K, <u>Okanoue T</u> , Itoh Y, Yoshikawa T	Oxidative stress may enhance the malignant potential of human hepatocellular carcinoma by telomerase activation.	Liver Int	29	846-856	2009
Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, <u>Okanoue T</u> , Yoshikawa T	Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease	Hepatol Res	39	366-373	2009
<u>Okanoue T</u> , Itoh Y, Minami M, Hashimoto H, Yasui K, Yotsuyanagi H, Takehara T, Kumada T, Tanaka E, Nishiguchi S, Izumi N, Sata M, Onji M, Yamada G, Okita K, Kumada H	Guidlines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts	Hepatol Int	38	27-36	2008
Mitsuyoshi H, Itoh Y, Sumida Y, Minami M, Yasui K, Nakashima T, <u>Okanoue T</u>	Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C	Hepatol Res	38	348-353	2008
Umemura A, Itoh Y, Itoh Y, Yamaguchi K,	Association of gankyrin protein expression with early clinical stages and	Hepatology	47	493-502	2008

Nakajima T, Higashitsuji H, Onoue H, Fukumoto M, Okanoue T, Fujita J	insulin-like growth factor-binding protein 5 expression in human hepatocellular carcinoma.				
Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y, Mitsuyoshi H, Minami M, Mitsufuji S, Tanaka S, Itoh Y, Nakamura Y, Taniwaki M, Arii S, <u>Okanoue T</u> , Yoshikwa T	ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotoxic entry.	Genes Chromosomes Cancer	48	109-120	2008
Hosoki T, Ikuta K, Shimonaka Y, Sasaki Y, Yasuno H, Sato K, Ohtake T, Sasaki K, Torimoto Y, Saito K, <u>Kohgo, Y</u>	Heterogeneous expressions of hepcidin isoforms in hepatoma-derived cells detected using simultaneous LC-MS/MS.	Proteomics -Clinical Applications	3	1256-1264	2009
Tsuchiya Y, Takahashi N, Yoshizaki T, Tanno S, Ohhira M, Motomura W, Tanno S, Takakusaki K, <u>Kohgo Y</u> , Okumura T	A Jak2 inhibitor, AG490, reverses lipin-1 suppression by TNF-alpha in 3T3-L1 adipocytes.	Biochem Biophys Res Communication s	382	348-352	2009
<u>Kohgo Y</u> , Ikuta K, Ohtake T, Torimoto Y, Kato J	Body iron metabolism and pathophysiology of iron overload.	Int J Hematol	88	7-15	2008
<u>Kohgo Y</u> , Ohtake T, Ikuta K, Suzuki Y,	Dysregulation of systemic iron metabolism in alcoholic liver diseases.	J Gastroenterol Hepatol	23 Supp 11	S78-81	2008

Torimoto Y, Kato J					
Ohhira M, Motomura W, Fukuda M, Yoshizaki T, Takahashi N, Tanno S, Wakamiya N, <u>Kohgo Y</u> , Kumei S, Okumura T	Lipopolysaccharide induces adipose differentiation-related protein expression and lipid accumulation in the liver through inhibition of fatty acid oxidation in mice.	J Gastroenterol	42	969-78	2007
<u>Kohgo Y</u> , Ikuta K, Otake T, Torimoto Y, Kato J	Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance.	World J Gastroenterol	13	4699-706	2007
Otake T, Saito H, Hosoki Y, Inoue M, Miyoshi S, Suzuki Y, Fujimoto Y, <u>Kohgo Y</u>	Hepcidin down-regulated in alcohol loading.	Alcohol Clin Exp Res	31 1 Supp 1	S2-8	2007
Yokozawa J, Sasaki T, Ohwada K, Sasaki Y, Ito J-I, Saito T, <u>Kawata S</u>	Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by an angiotensin II receptor blocker in the obese fa/fa/Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis	J Gastroenterol	44	583-591	2009
Saito T, Nishise Y, Makino N, Haga H, Ishii R, Okumoto K, Ito JI, Watanabe H, Saito K, Takeda H, Togashi H, Kubota I, Daimon M, Kato T, <u>Kawata S</u>	Impact of metabolic syndrome on elevated serum alanine aminotransferase levels in the Japanese population	Metabolism	58	1067-1075	2009
Ishizaka N, Ishizaka Y, Toda E, Yamakado M,	Impacts of changes in obesity parameters for the prediction of blood pressure change in	Kidney Blood Press Res	32	421-427	2009

<u>Koike K</u> , Nagai R.	Japanese individuals.				
Moriya K, Miyoshi H, Tsutsumi T, Shinzawa S, Fujie H, Shintani Y, Yotsuyanagi H, Moriishi K, Matsuura Y, Suzuki T, Miyamura T, <u>Koike K.</u>	Tacrolimus ameliorates metabolic disturbance and oxidative stress caused by hepatitis C virus core protein: Analysis using mouse model and cultured cells.	Am J Pathol	175	1515-1524	2009
Tsutsumi T, Matsuda M, Aizaki H, Moriya K, Miyoshi H, Fujie H, Shintani Y, Yotsuyanagi H, Miyamura T, Suzuki T, <u>Koike K.</u>	Proteomics analysis of mitochondrial proteins reveals overexpression of a mitochondrial protein chaperon, prohibitin, in cells expressing hepatitis C virus core protein.	Hepatology	50	378-386	2009
Yotsuyanagi H, Kikuchi Y, Tsukada K, Nishida K, Kato M, Sakai H, Takamatsu J, Hige S, Chayama K, Moriya K, <u>Koike K.</u>	Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter analysis.	Hepatol Res	39	657-663	2009

Ishizaka Y, Ishizaka N, Tani M, Toda A, Toda EI, <u>Koike</u> <u>K</u> , Nagai R, Yamakado M.	Association between changes in obesity parameters and incidence of chronic kidney disease in Japanese individuals.	Kidney Blood Press Res	32	141-149	2009
Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Uemura Y, Sakaida N, Fujisawa J, Seki T, <u>Koike K</u> , Okazaki K.	Hepatitis B virus X protein shifts human hepatic Transforming growth factor(tgf)- $\beta$ signaling from tumor-suppression to oncogenesis in early chronic hepatitis B.	Hepatology	49	1203-1217	2009
Yanagimoto S, Tatsuno K, Okugawa S, Kitazawa T, Tsukada K, <u>Koike K</u> , Kodama T, Kimura S, Shibasaki Y, Ota Y	A single amino acid of toll-like receptor 4 that is pivotal for its signal transduction and subcellular localization.	J Biol Chem	284	3513-3520	2009
Ishizaka N, Ishizaka Y, Yamakado M, Toda E, <u>Koike</u> <u>K</u> , Nagai R.	Association between metabolic syndrome and carotid atherosclerosis in individuals without diabetes based on the oral glucose tolerance test.	Atherosclerosis	204	619-623	2009
<u>Koike K</u>	Steatosis, Liver injury and hepatocarcinogenesis in hepatitis C viral infection.	J Gastroenterol	44 supl:	82-88	2009

Ichibangase T, Moriya K, <u>Koike K</u> , Imai K	Limitation of immunoaffinity column for the removal of abundant proteins from plasma in quantitative plasma proteomics.	Biomed Chromatogr	23	480-487	2009
Hashimoto H, Arai T, Mori A, Kawai K, Hikishima K, Ohnishi Y, Eto T, Ito M, Hioki K, Suzuki R, Ohsugi M, Saito M, Ueyama Y, Okano H, Yamauchi T, Kubota N, <u>Ueki</u> <u>K</u> , Tobe K, Tamaoki N, Kadowaki T, Kosaka K	Reconsideration of Insulin Signals Induced by Improved Laboratory Animal Diets, Japanese and American Diets, in IRS-2 Deficient Mice	Exp Clin Endocrinol Diabetes	117	576-586	2009
Awazawa M, <u>Ueki K</u> , Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T	Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway	Biochem Biophys Res Commun	382	51-56	2009
Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I,	Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and	J Biol Chem	284	1803-1812	2009

Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, Moroi M, Sugi K, Yamauchi T, Noda T, Nagai R, Terauchi Y, Tobe K, <u>Ueki</u> <u>K</u> , Kadowaki T	Adiponectin-independent Pathways.				
Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, <u>Ueki</u> K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R	CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.	Nat Med	15	914-920	2009
Takamatsu S, Noguchi N, kudo A, Nakamura N, Kawamura T, Teramoto K, Igari T, <u>Arii</u> S.	Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma.	Hepatogastroenterology	55	609-614	2008
Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S.	Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese	Hepatology	49	1636-44	2009

	and diabetic KK-Ay mice				
Takashima M, Parsons CJ, Ikejima K, <u>Watanabe S.</u> White ES, Rippe RA.	The tumor suppressor protein PTEN inhibits rat hepatic stellate cell activation	J. Gastroenterol.	44	847-855	2009
Piao N, Ikejima K, Kon K, Aoyama T, Osada T, Takei Y, Sato N, <u>Watanabe S.</u>	Synthetic triglyceride containing an arachidonic acid branch (8A8) prevents lipopolysaccharide-induced liver injury	Life Sci	85	617-24	2009
Tokushige K, <u>Hashimoto E</u> , Noto H, Yatsuji S, Tobari M, Torii N, Taniai M, Shiratori K, Murayama H	Clinical significance of serum ornithine carbamoyltransferase in patients with non-alcoholic steatohepatitis	Hepatol Res.	39	939-43	2009
Tokushige K, <u>Hashimoto E</u> , Noto H, Yatsuji S, Taniai M, Torii N, Shiratori K	Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease	J Gastroenterol	44	976-82.	2009
Tobari M, <u>Hashimoto E</u> , Yatsuji S, Torii N, Shiratori K	Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography	Intern Med	48	739-746	2009
<u>Hashimoto E</u> , Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K,	Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis	J Gastroenterol	44 Supp 119	89-95	2009

Shiratori K					
<u>Hashimoto E,</u> Farrell GC	Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?	J Gastroenterol Hepatol	24	501-503	2009
<u>Yatsuji S,</u> <u>Hashimoto E,</u> Tobari M, Taniai M, Tokushige K, Shiratori K	Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C	J Gastroenterol Hepatol	24	248-254	2009
<u>Yasui K,</u> Harano Y, Mitsuyoshi H, Tsuji K, Endo M, Nakajima T, Minami M, Itoh Y, Zen Y, Nakanuma Y, Yoshikawa T, Okanoue T	Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus	J Gastroenterol	45	95-104	2010
Dohi O, Takada H, Wakabayashi N, <u>Yasui K,</u> Sakakura C, Mitsufuji S, Naito Y, Taniwaki M, Yoshikawa T	Epigenetic silencing of RELN in gastric cancer	Int J Oncol	36	85-92	2010

Endo M, <u>Yasui K</u> , Nakajima T, Gen Y, Tsuji K, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M, Tanaka S, Arii S, Okanoue T, Yoshikawa T	Infrequent Amplification of JUN in Hepatocellular Carcinoma	Anticancer Res	29	4989-4994	2009
Zen K, <u>Yasui K</u> , Gen Y, Dohi O, Wakabayashi N, Mitsuishi S, Itoh Y, Zen Y, Nakanuma Y, Taniwaki M, Okanoue T, Yoshikawa T	Defective expression of polarity protein PAR-3 gene (PARD3) in esophageal squamous cell carcinoma	Oncogene	28	2910-2918	2009
Hikita H, <u>Takehara T</u> , Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, Kanto T, Hiramatsu N, Hennighausen L, Yin X, Hayashi N.	BH3-only protein bid participates in the Bcl-2 network in healthy liver cells	Hepatology	50	1972-1980	2009

Hikita H, <u>Takehara</u> T, Shimizu S, Kodama T, Li W, Miyagi T, Hosui A, Ishida H, Ohkawa K, Kanto T, Hiramatsu N, Yin X, Hennighausen L, Tatsumi T, Hayashi N.	Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver	Hepatology	50	1217-1226	2009
Kamada Y, <u>Takehara</u> T, Hayashi N	Adipocytokines and liver disease	J Gastroenterol	43	811-822	2008
Asanuma T, Ono M, Kubota K, Hirose A, Hayashi Y, <u>Saibara</u> T, Inanami O, Ogawa y, Enzan H, Onishi S, Kuwabara M, Oben JA.	Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease	Gut	59	258-266	2010
岡上武、 <u>西原利治</u> 、小野正文、角田圭雄、橋本悦子、田村信司、山田剛太郎、河田純男、工藤正俊	日本肝臓学会コンセンサス神戸 2009: NASH の診断と治療	肝臓	50	741-747	2009